Assessing Shattuck Labs: Insights From 6 Financial Analysts
During the last three months, 6 analysts shared their evaluations of Shattuck Labs (NASDAQ:STTK), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $16.67, a high estimate of $28.00, and a low estimate of $8.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.4%.
Deciphering Analyst Ratings: An In-Depth Analysis
An in-depth analysis of recent analyst actions unveils how financial experts perceive Shattuck Labs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gil Blum | Needham | Lowers | Buy | $8.00 | $12.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $28.00 | $28.00 |
| Gil Blum | Needham | Maintains | Buy | $12.00 | $12.00 |
| Gil Blum | Needham | Maintains | Buy | $12.00 | $12.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $28.00 | $28.00 |
| Gil Blum | Needham | Maintains | Buy | $12.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Shattuck Labs. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Shattuck Labs compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Shattuck Labs's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Shattuck Labs's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Shattuck Labs analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Shattuck Labs Better
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Unraveling the Financial Story of Shattuck Labs
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Shattuck Labs showcased positive performance, achieving a revenue growth rate of 1856.14% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Shattuck Labs's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -1659.55%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Shattuck Labs's ROE excels beyond industry benchmarks, reaching -13.53%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Shattuck Labs's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -12.1%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Shattuck Labs adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.